Objectives: To assess the feasibility and safety of a conservative approach to oxygen therapy in mechanically ventilated ICU patients. Design: Pilot prospective before-and-after study. Setting: A 22-bed multidisciplinary ICU of a tertiary care hospital in Australia. Patients: A total of 105 adult (18 years old or older) patients required mechanical ventilation for more than 48 hours: 51 patients during the "conventional" before period and 54 after a change to "conservative" oxygen therapy. Conclusions: Conservative oxygen therapy in mechanically ventilated ICU patients was feasible and free of adverse biochemical, physiological, or clinical outcomes while allowing a marked decrease in excess oxygen exposure. Our study supports the safety and feasibility of future pilot randomized controlled trials of conventional compared with conservative oxygen therapy. (Crit Care Med 2014; 42:1414-1422) Key Words: anoxia; critical illness; hyperoxia; lactic acid; oxygen inhalation therapy O xygen is the most widely prescribed therapy in mechanically ventilated ICU patients. The goal of oxygen therapy is to prevent or correct hypoxemia. The rationale for such intervention is that hypoxemia carries significant risk (1) . However, the prevention or treatment of hypoxemia may induce hyperoxemia, which may also be injurious (2, 3) . For example, a high Fio 2 may impair the innate immune response (4), cause lung injury, and induce interstitial fibrosis, atelectasis, tracheobronchitis, alveolar protein leakage, and infiltration by neutrophils (5-7). Systemically, hyperoxemia can increase vascular resistance, decrease cardiac output (7) (8) (9) (10) , and generate free radicals in various organs (11) . Clinical adverse outcomes of hyperoxemia have also been reported in patients with acute exacerbations of chronic obstructive pulmonary disease (12) , after cardiac arrest (13) , after abdominal surgery (14) , and in critical illness (15) .
Although there is increasing awareness of the potential harms of hyperoxemia, this concern has not translated to change in routine practice. Substantial excess oxygen delivery is frequent in mechanically ventilated patients (16) , and ventilator settings are not adjusted in most hyperoxemic cases (17) . A recent study showed that most episodes of hyperoxemia occurred at low Fio 2 and with average Spo 2 levels of greater than 98%, implying that further decreases in Fio 2 could be safely implemented (18) . However, no studies have shown the feasibility and/or safety of an approach to oxygen therapy deliberately targeting an oxygen saturation level between 90% and 92%.
Accordingly, we conducted a pilot prospective before-and-after trial of conservative oxygen therapy. We tested the hypothesis that a conservative approach to oxygen therapy (target Spo 2 of 90-92%) is feasible and safe in mechanically ventilated critically ill patients and can reduce exposure to excess oxygen.
MATERIALS AND METHODS

Study Design
We performed a prospective before-and-after pilot study in the 22-bed multidisciplinary ICU of the Austin Hospital, a tertiary care hospital affiliated with the University of Melbourne. The study was conducted from March 14, 2012 , to June 27, 2012 (conventional oxygen therapy period), followed by a phase-out period (from June 28, 2012, to October 15, 2012) and a conservative oxygen therapy period (October 16, 2012, to January 17, 2013). The study was approved by the human research ethics committee of the Austin Health with a waiver for informed consent because this was a practice change that applied to all admissions expected to require mechanical ventilation (MV) for greater than 48 hours (approval no. H2011/04252). The study is registered at ClinicalTrials.gov (NCT01684124).
Patients were eligible if they were adult (18 years old or older) and required MV for more than 48 hours. Patients were ineligible if they were either considered at risk for imminent death by the treating medical team or required extracorporeal membrane oxygenation. All patients received MV with an Evita 4, Evita XL (Drägerwerk AG, Lübeck, Germany) or an AVEA ventilator (CareFusion, Yorba Linda, CA). During the conventional period, oxygenation goals for each patient were prescribed at the discretion of bedside clinicians. All clinicians were kept strictly unaware of the study during this period. Following a phase-out period that included education and preparation of all ICU staff, the intervention period commenced with screening of all consecutive admissions. If a patient was eligible for the trial, clinicians now prescribed an Spo 2 level between 90% and 92% using the lowest possible Fio 2 .
Data Collection
Using a standardized case report form, we collected information on age, gender, type of admission, Acute Physiology and Chronic Health Evaluation (APACHE) III score, renal replacement therapy (RRT) at baseline (defined as that started within 24 hr after enrollment), primary admission diagnosis, and reason for MV. We recorded positive end-expiratory pressure (PEEP), ventilator-derived minute ventilation, Fio 2 , Spo 2 (Philips Healthcare, Eindhoven, The Netherlands), and Pao 2 as oxygenation-related variables. Simultaneously, we also collected blood pH, Paco 2 , hemoglobin concentration, lactate concentration, and creatinine concentration from blood gas analysis. Blood gas analysis was performed with ABL800 FLEX (Radiometer, Copenhagen, Denmark). We collected these data at four time points-06:00, 12:00, 18:00, and 24:00, using the measurement closest to that time point and followed up from the commencement of MV until the patient was free of MV for greater than 24 consecutive hours, death, or up to 28 days after enrollment into the study (whichever occurred first). For patients who were readmitted to ICU and required MV for greater than 48 hours, only the index admission was considered.
To avoid surveillance bias, we calculated the time-weighted averages for the oxygenation-related variables and blood gas results. The time-weighted value was determined by calculating the mean value between consecutive time points and multiplying it by the period of time between such points (19) . The sum of such time-weighted values is then divided by the total time to obtain the time-weighted average. We calculated the timeweighted average of all data for each patient as the time-weighted average during MV (TWA MV ). Similarly, we assumed the timeweighted average of four consecutive datasets of each day to be the time-weighted average for each 24-hour period (TWA 24 ). We excluded days when fewer than 12 hours of data were available for the day, for example, if the patient was extubated, had a brief spontaneous breathing with a T-piece circuit, did not have arterial blood gas data, had surgery, or died.
Oxygen utilization rate for each observation was calculated as follows: Minute ventilation × (Fio 2 -0.21)/0.79 (L/min) (20) , where total inspired gas flows were regarded as minute ventilation if patient had a brief spontaneous breathing with a T-piece circuit. A sum of their time-weighted value was regarded as a total amount of oxygen use during MV. When oxygen was delivered to a patient at hyperoxemia (defined as Spo 2 > 98% according to the British Thoracic Society guideline (21) and a recent review (22) that recommend target Spo 2 of 94-98% for most acutely ill patients) and continued without a decrease in Fio 2 despite an Spo 2 greater than 98% at the following set of observations, we defined such therapy as "excess oxygen delivery" and calculated the amount. Excess oxygen delivery rate for each observation was determined as minute ventilation × (Fio 2 -0.21) (L/min). A sum of their time-weighted values provided a total amount of excess oxygen delivery.
Outcomes
The primary outcome was change in Pao 2 /Fio 2 ratio in the first 10 days. Secondary and tertiary outcomes included changes in lactate and creatinine levels in the first 10 days; laboratory test results; new nonrespiratory organ failure while the patient was in ICU; the prevalence of arrhythmias, infection (defined as positive bacterial culture in sputum, urine, or blood), and severe hypoxemia (defined as Pao 2 < 55 torr) (23) in the ICU; acquired RRT (defined as that started 24 hr after enrollment) in the ICU; use of antidelirium drugs (haloperidol, olanzapine, quetiapine, and dexmedetomidine) and packed RBC transfusions in the ICU; ventilator-, ICU-, and hospital-free days at 28 days; and hospital survival status at 28 days. New nonrespiratory organ failure was defined as a Sequential Organ Failure Assessment (SOFA) score (24) of at least 3 for any of the cardiovascular, renal, hepatic, or hematological systems after day 2 in patients who did not have such organ failure at day 1 (25) . CNS (measured by the Glasgow coma score) was not considered because most patients received sedation. Statistical Analysis A minimum of 45 patients per group (90 patients total) were required to detect a difference of 0.6 sds of relative change in Pao 2 /Fio 2 ratio from baseline to the worst value between the two groups with 95% certainty at 80% power. Target recruitment was set at 50 patients per group.
Variables were assessed for normality. Baseline comparisons were performed using Fisher exact tests and reported as n (%). Continuous normally distributed variables were compared using Student t tests and reported as means (sd), while nonnormally distributed data were compared using Wilcoxon rank-sum tests and reported as medians (interquartile range). Changes over time were determined using repeated-measures mixed linear modeling with each patient treated as a random effect, and therapy group, time, and the interaction of therapy group and time as effect-fixed effects. Variables were log-transformed if appropriate in this model.
Trends over time in achieved Spo 2 , Pao 2 , and Fio 2 were assessed for the first 10 days. We calculated the time spent in predefined bands of the variables of interest (Fio 2 , Spo 2 , and Pao 2 ) assuming a linear trend between individual measurements and expressing the result as a proportion of the whole duration of MV. The band was defined as follows: Fio 2 was divided into eight bands of 0.1; Spo 2 above 89% was divided into 11 bands of 1%; and Pao 2 was divided into four bands (≤ 60, 60-80, 80-120, and > 120 torr).
To investigate the clinicians' response when Fio 2 was relatively low (< 0.5), we assessed whether, in the subsequent dataset, Fio 2 was adjusted according to Spo 2 levels. These frequencies were compared between groups by the chi-square test. Additionally, we evaluated adherence to the target Spo 2 in the conservative oxygen therapy group.
Changes in the relevant outcome variables (Pao 2 /Fio 2 ratio, lactate, and creatinine) were expressed as relative percentage change from baseline. The first result after the commencement of MV was referred to as "baseline value." Changes from baseline to follow-up over the first 10 days, the worst value (%∆worst), TWA 24 on day 1 (%∆24 hr), and TWA 24 on day 2 (%∆48 hr) were assessed.
A multivariable logistic regression analysis was performed to estimate the risk for various clinical outcomes with the conservative oxygen therapy, adjusting for APACHE III score, primary diagnosis, and reason for MV. A multivariable linear regression analysis was also conducted to assess the relationship between the conservative oxygen therapy and the relevant outcome variables. Because the magnitude of the increase in lactate and creatinine levels could be dependent on the use of RRT, the use of RRT during ICU (including both RRT at baseline and acquired RRT) was also included as an independent factor in this model. All analysis was performed using SPSS version 19.0 (SPSS, Chicago, IL). To account for multiple comparisons and further reduce the chance of a type I error, a two-sided p value of 0.01 was used to indicate statistical significance.
Sensitivity Analysis
Because several extra patients were enrolled in this trial in case of missing data, to assess the robustness of our results, all above analyses were repeated for the first 50 patients in each group. Furthermore, we carried out additional analysis using all available blood gas results from all study patients during the whole MV period to assess change in Pao 2 /Fio 2 ratio and lactate and creatinine levels in the first 10 days. The blood gas results used here were stored electronically and retrieved.
RESULTS
Patient Characteristics
During the study period, there were 678 admissions from 625 patients during the before period and 498 admissions from 451 patients during the conservative oxygen therapy period.
We enrolled 51 patients with 1,409 datasets on 354 MV days in the conventional therapy group and 54 patients with 1,760 datasets on 445 MV days in the conservative oxygen therapy group. The two groups of patients had similar baseline characteristics ( Table 1) . Over the first 10 days, significantly lower levels of Spo 2 , Pao 2 , and Fio 2 were observed in the conservative group (Fig. 1) . Conservative oxygen therapy decreased the total amount of oxygen delivered during MV by approximately two thirds (15, (Fig. 2C) . In the conservative oxygen therapy group, percentage of time spent with hyperoxemia significantly decreased (13% [2-36%]) ( Fig. 2A; (Fig. 3C) . Importantly, while the conventional group essentially spent no time at an Fio 2 of 0.21 (0% [0-0%]), the conservative oxygen therapy group spent 33% (9-73%) of the time at an Fio 2 of 0.21 (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A848).
Conservative Oxygen Therapy and Treatment Effect
After excluding the first data of each patient and data observed while on an Fio 2 of 0.21, the distribution of Spo 2 peaked at 93% and a total of 21% of the observations were in the target range (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A848). Finally, when an Spo 2 was above the target levels with an Fio 2 below 0.5 (but not already 0.21), the Fio 2 was more frequently decreased in the conservative therapy group ( Table 2 ). and follow-up in the first 10 days were also analyzed (Fig. 3) . No differences were found in Pao 2 /Fio 2 ratio (Fig. 3A) and creatinine levels (Fig. 3C ), but the conservative oxygen therapy group had a trend toward decreasing lactate levels over the first 10 days (p = 0.08) (Fig. 3B ). There were no significant differences in any other clinical outcomes (Supplemental Table 3 , Supplemental Digital Content 1, http://links. lww.com/CCM/A848).
On multivariable regression analysis, conservative oxygen therapy continued to show a trend toward decreases in lactate levels between baseline and the worst value and between baseline and day 2 (standardized coefficients of -0.18, p = 0.093 and standardized coefficients of -0.20, p = 0.050, respectively) ( Table 3 ). There was a trend toward a decrease in the risk of new nonrespiratory organ failure in conservative oxygen therapy group (adjusted odds ratio, 0.32; 95% CI, 0.12-0.83; p = 0.019) ( Table 4 ). The direction of these results essentially remained unchanged when we performed sensitivity analysis in the first 50 patients in each group (supplemental data, Supplemental Digital Content 1, http://links.lww.com/CCM/ A848) or used all available blood gas results collected from all study patients during their whole MV period (Supplemental 
DISCUSSION
Key Findings
We conducted a pilot feasibility and safety before-and-after trial of conservative oxygen therapy in mechanically ventilated patients in the setting of an Australian tertiary ICU. An oxygen therapy approach targeting an oxygen saturation of 90-92% achieved significantly lower Spo 2 and Pao 2 levels and marked oxygen exposure. The changes in Pao 2 /Fio 2 ratio from baseline did not differ between conservative and conventional oxygen therapy. There was no significant difference between groups in any other secondary outcome although conservative oxygen therapy was associated with a trend toward the decrease in the risk for nonrespiratory organ failure and lactate concentrations.
Relationship to Previous Findings
Previous observational studies have shown that a "liberal" approach to oxygen therapy is dominant in mechanically ventilated patients in ICU. In a Dutch multicenter retrospective observational study involving thousands of patients, hyperoxemia (defined as Pao 2 > 120 torr) was frequent (22%) and, even when the Fio 2 was 0.4 or lower, the Fio 2 was decreased in only 6% of cases (17) . Furthermore, 74% of MV patients at the Mayo Clinic were exposed to excessive Fio 2 for a median duration of 17 hours (16) . Concern over such liberal use of supplemental oxygen has recently gained increased prominence (2, 3, 26, 27) arguing that avoidance of unnecessary exposure to hyperoxemia is likely to be desirable. To our knowledge, however, ours is the first study investigating the feasibility, safety, and physiological consequences of lower Spo 2 targets in mechanically ventilated ICU adult patients. Implementing a more conservative oxygen therapy protocol produced a clear separation in Spo 2 , Pao 2 , and Fio 2 compared with our standard preintervention liberal oxygen therapy group and also with previous observational studies of oxygen administration practice in patients receiving MV in ICU (16, 17) . The acute respiratory distress syndrome (ARDS) Network study comparing higher versus lower PEEP resulted in a statistically significant difference in Fio 2 and found no adverse association with such changes (28) . The British Thoracic Society guideline (21) and a recent review (22) recommended target Spo 2 of 94-98% for most acutely ill patients even though the guidelines do not apply to mechanically ventilated patients, and evidence supporting such recommendations is lacking. Thus, for patients receiving MV, the optimal Spo 2 target levels remain unclear.
The greatest concern with conservative oxygen therapy in mechanically ventilated patients is the prevalence of severe hypoxemia and increased risk of tissue hypoxia which may cause the development of organ failure. Employing an Spo 2 target of 92% and 90% in mechanically ventilated patients led to 80% and 35%, respectively, of Pao 2 values being greater than or equal to 60 torr (23) . In our conservative group, the percentage of time spent with a Pao 2 less than or equal to 60 torr was negligible. Furthermore, oxygen administration decreases cardiac output; systemic and coronary oxygen delivery (29) ; and cortical cerebral blood flow (30) while increasing oxidative stress (31) . These factors may explain the trend we observed toward decreased risk for new nonrespiratory organ failure in the conservative therapy group.
We found a trend to greater relative decrease in lactate from baseline in the conservative oxygen therapy group. The lung is a substantial source of lactate during ARDS or endotoxemia (32) (33) (34) and in critically ill patients (35) . Such lung lactate production is associated with lung injury score (32) suggesting that lactate generation was not attributable to lung tissue hypoxemia (36) . Prolonged exposure to a high Fio 2 causes histopathological changes similar to those seen in ARDS and exacerbated ventilator-induced lung injury (2) . Even a moderate Fio 2 of 0.5 has been reported to cause lung injury and changes in lung tissue compared with air in experimental models (37) . Additionally, ventilation with oxygen (6 hr) even at ambient air level (21%) increases tissue volumes, myofibroblast differentiation, and apoptosis in the sheep immature lung compared to nitrogen alone (38) . On the other hand, in a recent study, a relatively low Fio 2 of 0.4 in mechanically ventilated patients without respiratory failure did not induce detectable inflammatory effects (39) . However, inflammation may be a secondary event rather than a causal factor in lung injury (40) while the generation of reactive oxygen species may play a greater role in epithelial cell death and hyperoxemia-induced lung injury (40, 41) . Thus, the effect of relatively low dose oxygen on lung remains uncertain.
Clinical Implications
Our findings suggest that an oxygen therapy protocol targeting an Spo 2 between 90% and 92% is feasible, can be safely implemented for mechanically ventilated patients in ICU, and leads to a marked decrease on oxygen exposure. These findings are important because a lower Spo 2 may be a potential therapeutic target for randomized controlled trials, particularly in patients with ARDS who die more often of multiple organ failure than hypoxemia (42) . Our study also opens the door to phase II randomized controlled trials of conventional compared with conservative oxygen therapy.
Strengths and Limitations
To our knowledge, this is the first study to compare two different Spo 2 targets in mechanically ventilated patients in ICU. To make our findings robust, we additionally analyzed a total of 5,735 blood gas results in the study patients collected during the whole MV period as part of a sensitivity analysis. However, our study has several limitations. Before-and-after design is subject to secular changes that may have led to independent improvements in care. Additionally, the two study periods enrolled patients during a different time of the year, and thus we could not exclude a seasonal effect. However, in our ICU, in the period after the intervention, there had been secular trends toward a greater use of RRT and stable hospital mortality (Supplemental Table 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/A848).
As we mentioned earlier, the median TWA MV -Spo 2 achieved in the conservative group was above the target level. This is at least partially explained by the fact that 45% of the results in the conservative group were observed at an Fio 2 of 0.21 and further titration was impossible. However, after excluding such data and the first dataset for each patient, about 50% of the observations with the Spo 2 above the target levels failed to lead to adjustments in Fio 2 . Because the peak of the distribution of Spo 2 among such observations was 93%, it appears that implementation was not complete and that clinicians and nurses tolerated an Spo 2 around the upper limit of the study target. Nonetheless, the prescribed approach markedly decreased the total amount of oxygen usage.
Although they were not statistically significant, there were imbalances in patient baseline characteristics such as primary diagnosis and reasons for MV. We therefore used multivariable analysis to control for potentially confounding effects.
Because Pao 2 /Fio 2 ratio could conceivably be affected by Fio 2 when there is any significant degree of shunt (43) , a change in Pao 2 /Fio 2 ratio may not be insufficient in detecting pulmonary injury. However, Pao 2 /Fio 2 ratio is frequently assessed and widely and easily understood and calculated in clinical practice; it is used in the Berlin definition of ARDS (44) and in several severity scoring systems such as SOFA score (24) and Simplified Acute Physiology Score II (45) .
We did not collect data on tidal volume during the study period. Larger tidal volume is associated with the risk of development of lung injury in mechanically ventilated ICU patients (46) . However, the typical target tidal volume in our unit is between 6 and 8 mL/kg and this was not changed during the study period.
The current study may be underpowered for all of secondary outcomes and multivariable analysis because the sample size calculation was based on Pao 2 /Fio 2 and the number of the outcome events was small. Additionally, outcomes such as MV-, ICU-, and hospital-free days in multivariable linear regression analysis did not follow normal distributions and meet the assumptions required for this analysis. Therefore, these results must be interpreted with caution. Although there was a large CI, the adjusted odds ratio of acquired RRT in the conservative therapy group was 2.90. Renal adverse effect of conservative oxygen therapy cannot be excluded.
Our findings need to be confirmed or refuted in different healthcare systems and different ICUs. The feasibility and safety of more strict approaches to Spo 2 targeting (47, 48) may also require testing in future studies.
CONCLUSIONS
Our preliminary data suggest that implementing an oxygen therapy target of Spo 2 of 90-92% in mechanically ventilated ICU patients is feasible and not associated with major clinical or physiological adverse events. Our findings support the safety and feasibility of future randomized controlled trials of conservative versus conventional oxygen therapy.
